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1528Variation in Management of Immune Suppression after
Allogeneic Hematopoietic Cell Transplantation
Joseph Pidala,1,3 Stephanie J. Lee,2 Gwen Quinn,3,5 Heather Jim,3,5
Jongphil Kim,3,4 Claudio Anasetti1,3Practice variation in transplant physician management of immune suppression (IS) after allogeneic hemato-
poietic cell transplantation (HCT) is anticipated to have important consequences, but has not been
characterized to date. We conducted a national survey of transplant physician members of the American
Society for Blood and Marrow Transplantation to discern variation in IS management, characterize the bur-
den of graft-versus-host disease (GVHD) emerging in the setting of IS taper, and describe the proportion of
HCTrecipients who successfully discontinue IS by 2 and 5 years post-HCT. There was marked heterogeneity
in IS discontinuation practice, with variation in initiation of taper, sequence of agents tapered, frequency of
changes, and strategy utilized. Twenty-five percent reported no consistent strategy in their usual practice.
Confidence in therapeutic decision making was limited. The majority indicated that they could not predict
who would develop GVHD on taper of IS, and reported a resultant burden of both acute and chronic
GVHD (aGVHD, cGVHD) emerging or recurring in the setting of IS taper. HCT physicians projected rates
of IS discontinuation that increased from 2 to 5 years post-HCT, and differed significantly according to donor
relation and stem cell source utilized. The marked variation in practice, burden of GVHD emerging in the
setting of IS taper, and limited confidence in therapeutic decision making all highlight shortcomings in an
essential component of HCT physicians’ scope of practice. These data argue for more rigorous study of IS
management post-HCT so that evidence-based practice guidelines can be developed.
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Although significant advances have been made in
the prevention and therapy of acute and chronic
graft-versus-host disease (aGVHD, cGVHD) [1-6],
less systematic attention has been directed to
management of immune suppression (IS) after
allogeneic hematopoietic cell transplantation (HCT)
and the problem of recurrent GVHD in this setting.
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6/j.bbmt.2011.03.006most recipients of allogeneic HCT will eventually
discontinue IS, thereafter maintaining a state of
immune tolerance. However, there is little published
data on the rates of successful rates of IS dis-
continuation after HCT [7]. As well, current practice
in management of immunosuppressive agents after
HCT is empiric and circumscribed by the inability
of physicians to discern which patients can safely taper
or discontinue immunosuppressive agents. Drug-
suppressed immune response cannot be distinguished
from the development of immune tolerance based on
clinical assessment, and therefore attempts at IS dis-
continuation are often met with emergence or recur-
rence of aGVHD and cGVHD.
The optimal duration of IS administration is not
known. Investigators have studied the impact of
prolonged cyclosporine (CSA) administration after
HCT on the incidence of aGVHD and cGVHD, but
with mixed conclusions. Although some reports indi-
cated decreased risk with prolonged administration
of CSA [8,9], prospective trials have not consistently
demonstrated a benefit. In a randomized trial of
allogeneic related or unrelated marrow transplant
recipients, the hazard for development of cGVHD
did not significantly differ between 6 and 24 months
Biol Blood Marrow Transplant 17:1528-1536, 2011 1529Variation in Immune Suppression Managementof CSA administration post-HCT [10]. Others have
demonstrated in peripheral blood stem cell (PBSC)
grafts frommatched related donors significantly reduced
incidence of cGVHD in those treated with 12 versus 6
months of CSA post-HCT [11]. In the setting of non-
myeloablativeHCT, retrospective analysis did not dem-
onstrate significant differences in rates of extensive
cGVHD among 3 tapering schedules [12]. These pub-
lished data and unpublished observations indicate varia-
tion in center-based and individual transplant physician
practice in themanagement of IS afterHCT.This prac-
tice variationhasnot been formally characterized todate.
Heterogeneity in physician practice has been
demonstrated in a number of important studies in
the field of HCT, demonstrating variation in the
following: aGVHD prophylaxis and therapy [13]; anti-
microbial prophylaxis [14]; diagnosis, grading,
and management of cGVHD [15]; management of
steroid-refractory aGVHD [16]; recommendation for
transplantation therapy, timing of this therapy, and
transplantation conditions [17]; and pretransplanta-
tion evaluation and supportive care practices [18].
To examine the variation in transplant physician
management of IS, characterize the burden of
GVHD incurred in this setting, and to describe the
proportion of patients who are able to successfully dis-
continue IS after transplantation, we conducted a vi-
gnette-based national survey of HCT physicians
through the American Society for Blood and Marrow
Transplantation (ASBMT).METHODS
Development of Survey
The survey was developed to describe vignette-
based clinical scenarios that require decisions on IS
management after allogeneic HCT. Vignettes were
utilized so that standardized information could be pre-
sented to respondents to facilitate decision making.
Following a base case, each additional vignette was
constructed to differ by 1 variable to examine how
the practices differed according to each variable. These
were organized to reflect nuances in HCT conditions
that may impact IS management decisions, including
hematopoietic stem cell source (peripheral blood mo-
bilized versus bonemarrow [BM] harvested), donor re-
lation (matched related versus matched unrelated), and
conditioning regimen intensity (myeloablative versus
reduced intensity). Because there is potential variation
in practice according to conditions treated with HCT,
all vignettes were standardized to describe only acute
myelogenous leukemia (AML). AML was chosen, be-
cause it is currently the most common indication for
allogeneic HCT. Additional vignettes examined deci-
sion making with AML recurrence after HCT, and
after successful treatment of aGVHD and cGVHD.The survey was developed by the authors, and then
tested with transplant physicians at the Moffitt Cancer
Center and FredHutchinsonCancer Research Center.
Survey items were modified based on feedback
obtained on the following elements: content validity,
face validity, presentation of information, ability of
survey respondent to interpret the essential informa-
tion and understand each item, as well as ability
to complete the survey within the anticipated time.
The final survey instrument consisted of 7 clinical
vignettes, 34 associated questions examining practice
in response to these vignettes, and an additional 17
questions on the respondent’s perception of sociode-
mographic and transplant practice characteristics.
These included characteristics of physician practice
(transplant center, pediatric versus adult transplanta-
tion practice, years of experience as a transplant physi-
cian, academic versus clinical practice setting, percent
of practice comprised of clinical versus research or
administrative responsibilities, and number of faculty
in the transplant group), characteristics of allogeneic
transplant patients treated at the respondent’s center
(number of HCT performed per year, proportion
performed with myeloablative conditioning, propor-
tion of related versus unrelated donors, proportion
with matched donors, proportion of unrelated donors
utilizing umbilical cord blood, median age of trans-
plant recipients, proportion utilizing peripheral blood
versus BM stem cells, and proportion in remission at
time of transplantation), and self-reported proportion
of HCT patients with aGVHD and cGVHD. The
survey was anticipated to take 10 to 15 minutes to
complete.
Survey Distribution and Data Collection
This study was approved by the University of South
Florida institutional review board as a national survey of
transplant physician practice. The requirement for
signed informed consent for participation was waived.
The electronic, Internet-based survey was maintained
by the Survey Methods Core Program at the Moffitt
Cancer Center. Invitation to ASBMTmembers to par-
ticipate was facilitated by e-mail notification by the
ASBMT. Potential respondents were provided a link
to the electronic survey, which described the nature of
the study, potential risks and benefits involved, lack of
financial or other reimbursement for participation,
and the right to decline participation.
Statistical Methods
The intent of this study was exploratory in nature
without a priori hypotheses. Descriptive statistics were
utilized to summarize responses for items related to each
clinical vignette and the subsequent sociodemographic
and transplantation items. Association between item
responses and survey respondent sociodemographic and
1530 Biol Blood Marrow Transplant 17:1528-1536, 2011J. Pidala et al.transplantation practice variables were explored with the
chi-square, Gamma test, or Cochran-Armitage trend
test as appropriate per the nature of the variables
examined.RESULTS
Characteristics of Survey Respondents
The initial notification was distributed by the
ASBMTonDecember 14, 2009. Two reminder e-mails
followed on January 12, 2010, and February 8, 2010.
Two additional targeted e-mail invitations were sent
to nonresponders on May 4 and 11, 2010. The total
number of recipients was 1457. From this sample, a total
of 1100 were transplant physicians. Undeliverable or
returned messages were not tracked by the ASBMT.
Of the 1457 recipients, 2 actively declined to participate.
A total of 225 respondents completed the survey,
resulting in an overall response rate of 15% and a physi-
cian response rate of 21%. This was lower than the
anticipated response [19-21]. A total of 74 responded
after the first notification, 57 after the second, and
48 after the third notification. An additional 22
and 24 responded after 2 targeted invitations to
nonresponders, respectively. The self-reported HCT
physician demographic, HCT center and patient, and
baseline GVHD characteristics are summarized in
Table 1.IS Management Post-HCT
The base case of the survey described a 35-year-old
man with AML with normal cytogenetics in his first
complete remission, whowas treatedwith amyeloabla-
tive regimen (cyclophosphamide and total-body
irradiation) followed bymatched sibling donor periph-
eral bloodHCT. Survey respondents were asked to de-
scribe their usual practice of IS management in this
setting. Figure 1 depicts the frequency distribution of
time of initiation of taper of any IS agents used in
GVHD prophylaxis in the absence of any clinical
GVHD.
Respondents most frequently indicated an IS taper
initiation between days 100 and 149 post-HCT. IS
taper start date was significantly associated with the
following factors: Physicians treating pediatric pa-
tients who underwent HCT started the IS taper earlier
than physicians who treated adults (P 5 .004). Earlier
IS taper start date was also associated with a greater
proportion of myeloablative regimens utilized (P 5
.036) and a greater proportion of HCT patients in re-
mission at the time of HCT (P\ .001). Of those who
indicated use of cyclosporine as GVHD prophylaxis,
53% indicated they would taper this agent first. Of
those indicating the use of tacrolimus for GVHD pro-
phylaxis, 45% indicated they would taper this first.From those using mycophenolate mofetil in GVHD
prophylaxis, 71% indicated that they would first taper
this agent. Finally, of those indicating use of sirolimus
in GVHD prophylaxis, 20% indicated that they would
taper this agent first.
There was considerable variation in the strategy
utilized for IS taper: 56 (25%) indicated that they
followed no consistent strategy; 121 (55%) tapered
by percent dose reduction (eg, 10% reduction); and
44 (20%) tapered according to fixed dose reduction
(eg, by 0.5 mg). Heterogeneity was also observed in
the frequency of IS taper: days, or less than weekly 8
(4%); weekly 100 (45%); biweekly 88 (40%); monthly
19 (9%); every 6 weeks 4 (2%); bimonthly 2 (1%); none
indicated taper on a greater than every 2 month basis.
Significant associations were detected between the fre-
quency of IS taper and the following factors: those with
an institutional practice guideline or protocol for IS
management tapered more frequently (P 5 .002);
those indicating less comfort in decision making ta-
pered less frequently (P5 .016); adult HCTphysicians
tapered less frequently than pediatric (P 5 .009);
a greater proportion of peripheral blood HCT utilized
was associated with less frequent IS taper (P 5 .008);
and greater utilization of cord blood HCT was associ-
ated with more frequent IS taper (P 5 .007).
A second clinical vignette mirrored the first, with
the exception of utilization of BM harvested stem cells
rather than PBSCs. The majority of respondents
(82%) indicated that stem cell source does not influence
their practice of IS management after HCT. Of those
who did indicate differential practice according to
stem cell source, the majority (83%) indicated earlier
start of IS taper with BM compared with peripheral
blood stem cell transplantation (PBSCT). Use of simi-
lar ISmanagement strategies for PBSC and BMwas sig-
nificantly associated with self-report of the ability to
distinguish those who will develop GVHD on IS taper
(P5 .009), adult versus pediatric HCT physician status
(P 5 .006), and older age of the respondent’s center
HCT patients (P 5 .005).
A third vignette mirrored the base case, with the
exception that it depicted the use of a matched unre-
lated donor peripheral blood HCT. Forty-three
percent of respondents indicated no difference in their
management of IS agents after HCT in the setting of
matched unrelated donor versus matched sibling do-
nor HCT. Of those who did indicate differential man-
agement, the majority (87%) started IS taper later after
unrelated donor HCT. Sixteen percent reported ta-
pering less frequently, and 18% indicated tapering by
lesser amounts. Similar approaches to IS management
after unrelated and related donor HCT was associated
with a larger number of faculty in the BMT group (P5
.012), more HCT performed/year (P \ .0001), and
greater degree of agreement with the statement, ‘‘my
current strategy for IS taper is adequate’’ (P 5 .045).
Table 1. Survey Respondent Self-Report of HCT Physician,
HCT Center, and Patient, and Baseline GVHD and GVHD
Prophylaxis Characteristics
HCT Physician Characteristics Number (%)
Practice setting
Academic 192 (87%)
Community 28 (13%)
% effort in clinical duties
<20% 8 (4%)
20% to 39% 31 (14%)
40% to 59% 62 (28%)
60% to 79% 74 (33%)
80% to 100% 46 (21%)
Duration of practice as HCT physician
Fellow/training 8 (4%)
<5 years 32 (15%)
5 to 9 years 78 (35%)
10 to 14 years 34 (15%)
15 to 19 years 68 (31%)
$20 years 0 (0%)
Number of HCT faculty in group
<5 81 (37%)
5 to 9 94 (43%)
10 to 14 24 (11%)
15 to 19 12 (5%)
$20 10 (5%)
Adult 178 (81%)
Pediatric 43 (19%)
HCT Center and Patient
Characteristics Number (%)
# HCT/year
<25 39 (18%)
25 to 49 56 (25%)
50 to 99 61 (28%)
100 to 149 29 (13%)
150 to 199 9 (4%)
$200 27 (12%)
Median age HCT patients
<20 36 (17%)
20 to 39 20 (9%)
40 to 59 156 (72%)
$60 6 (3%)
% in remission at HCT
<25% 3 (1%)
25% to 49% 27 (12%)
50% to 74% 72 (33%)
75% to 100% 117 (53%)
% PBSCs
<25% 35 (16%)
25% to 49% 19 (9%)
50% to 74% 55 (25%)
75% to 100% 109 (50%)
% related donors
<25% 31 (14%)
25% to 49% 123 (56%)
50% to 74% 47 (21%)
75% to 100% 19 (9%)
% HLA matched
<25% 8 (4%)
25% to 49% 36 (16%)
50% to 74% 64 (29%)
75% to 100% 111 (51%)
% RIC or NMA
<25% 23 (10%)
25% to 49% 84 (38%)
50% to 74% 87 (40%)
75% to 100% 26 (12%)
% unrelated donor utilizing cord blood
<25% 169 (78%)
25% to 49% 24 (11%)
(Continued )
Table 1. (Continued )
HCT Center and Patient
Characteristics Number (%)
50% to 74% 16 (7%)
75% to 100% 9 (4%)
GVHD Characteristics Number (%)
GVHD prophylaxis
CSA/MTX
<20% 45 (28%)
20% to 29% 34 (22%)
40% to 59% 25 (16%)
60% to 79% 31 (20%)
80% to 100% 23 (15%)
CSA/MMF
<20% 51 (40%)
20% to 29% 39 (31%)
40% to 59% 17 (13%)
60% to 79% 13 (10%)
80% to 100% 7 (6%)
TAC/MTX
<20% 29 (21%)
20% to 29% 31 (23%)
40% to 59% 27 (20%)
60% to 79% 29 (21%)
80% to 100% 21 (15%)
TAC/MMF
<20% 53 (48%)
20% to 29% 27 (24%)
40% to 59% 18 (16%)
60% to 79% 6 (5%)
80% to 100% 7 (6%)
TAC/SIR
<20% 53 (66%)
20% to 29% 15 (19%)
40% to 59% 5 (6%)
60% to 79% 5 (6%)
80% to 100% 2 (3%)
Proportion with II-IV acute GVHD
<25% 29 (13%)
25% to 49% 129 (59%)
50% to 74% 58 (26%)
75% to 100% 4 (2%)
Proportion with moderate/severe
chronic GVHD
<25% 51 (23%)
25% to 49% 115 (52%)
50% to 74% 52 (24%)
75% to 100% 2 (1%)
HCT indicates allogeneic hematopoietic cell transplantation; GVHD,
graft-versus-host disease; PBSCs, peripheral blood stem cells; HLA,
human leukocyte antigen; RIC, reduced-intensity conditioning; NMA,
nonmyeloablative; CSA, cyclosporine; MTX, methotrexate; MMF, myco-
phenolate mofetil; TAC, tacrolimus; SIR, sirolimus.
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with the exception of the use of a reduced-intensity
conditioning (RIC) regimen. Forty percent of
respondents indicated no difference in their manage-
ment of IS following RIC compared with myeloabla-
tive conditioning therapy. Of the remainder, 60%
reported tapering earlier, and 34% indicated that their
IS management in the setting of RIC is determined by
donor chimerism post-HCT. No difference in man-
agement by physicians was significantly associated
with adult versus pediatric HCT (P 5 .01), a larger
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Figure 1. Frequency histogram of reported day post-HCT for initia-
tion of immune suppression taper.
1532 Biol Blood Marrow Transplant 17:1528-1536, 2011J. Pidala et al.number of HCT/year (P5 .004), and a higher median
age of HCT recipients (P 5 .005).Management of IS after Relapse
In a fifth vignette, respondents described their man-
agement of IS in the case of a 35-year-old man with
relapsed AML (peripheral blood cytopenias, 26%
myeloblasts on BM) by day 60 after a prior myeloabla-
tive HCT utilizing matched sibling donor PBSCs.
Twenty-four percent tapered IS, and 71% endorsed
completely discontinuing all IS agents. Fifty percent de-
livered donor-lymphocyte infusion (DLI), and 48%
treated with chemotherapy. Discontinuation of all IS
was associated with a feeling of adequacy of IS strategy
(P 5 .003), decreased number of faculty in the group
(P 5 .0003), decreased number of HCT/year per-
formed (P\ .0001), and a lesser median age of HCT
patients treated (P 5 .03). Delivery of chemotherapy
was associated with a larger number of HCT/year per-
formed (P 5 .02). When presented with aGVHD fol-
lowing DLI, 2% reported no change in management,
38% resumed prior IS agents stopped after relapse de-
veloped, 72% added systemic glucocorticoid therapy,
and 10% started additional nonsteroid IS agents. No
change to IS therapy in the setting of aGVHD follow-
ing DLI was associated with a shorter duration of
practice as an HCT physician (P 5 .027). DLI admin-
istration, resumption of prior IS agents, and addition
of steroids all differed according to adult versus pediat-
ric HCT physician status (all P\ .05). Interestingly,
58% of respondents indicated that they either agreed
or strongly agreed with the statement, ‘‘I am willing
to accept grade II-IV aGVHD that develops in the set-
ting of stopping IS agents and DLI if there is primary
disease relapse after HCT.’’ Agreement with this state-
ment was associated with a longer duration of practice
as an HCT physician (P\ .0001).Management of IS after Resolution of GVHD
In a sixth vignette, respondents were asked to
describe their management of IS after the resolution
of an overall grade III biopsy confirmed aGVHD of
the skin and gastrointestinal (GI) tract on day 30 in
the case of the patient originally described in vignette
1. He was described as having achieved a complete re-
mission of aGVHD manifestations after 1 mg/kg of
steroid therapy. Seventeen percent indicated that they
would taper steroids immediately upon resolution of
the aGVHD manifestations. Others reported tapering
steroids after a postresolution period of days (11%),
1week (25%), 2weeks (29%), 1month (11%), 2months
(1%), or .2 months (1%). Allowing a longer period
following resolution of aGVHD before tapering
glucocorticoid therapy was associated with community
practice setting (P5 .03), smaller number ofHCT/year
performed (P5 .006), and youngermedian age ofHCT
patients (P5 .02). Nonsteroid IS agents were tapered at
the following time points: with active aGVHD (1%),
immediately upon resolution (2%), within days (1%),
1 week (3%), 2 weeks (7%), 1 month (27%), 2 months
(19%), and .2 months (40%).
In the final vignette, the original base case patient
was depicted as having developed at day 120 post-
HCT cGVHD including lichen planus-like changes
in the mouth without limitation in oral intake, sicca
syndrome requiring eye drops twice daily, arthralgias,
and new increase in liver function tests at 2 the upper
limit of normal; these manifestations were then
described as completely resolved after 1 mg/kg of
glucocorticoid therapy. There was marked variation
in timing of glucocorticoid taper: taper with active
cGVHD (6%), immediately on resolution (10%),
days (4%), 1 week (11%), 2 weeks (24%), 1 month
(28%), 2 months (9%), and.2 months (7%). Nonste-
roid agents were tapered at the following: with active
cGVHD (2%), at resolution (1%), days (1%), 1 week
(1%), 2 weeks (4%), 1 month (19%), 2 months
(19%), and .2 months (53%).GVHD following IS Taper
Following each previously described clinical
vignette, survey respondents were asked to estimate
the frequency at which they observe recurrent
aGVHD following the taper of IS agents. The fre-
quency distribution across these clinical vignettes is
depicted in Figure 2. With the exception of the com-
parison of myeloablative conditioning with PBSCT
and RIC PBSCT, the distributions between groups
significantly differed.
When presented with the occurrence of recurrent
aGVHD following IS taper, respondents varied in their
management strategy: 44% resumed the original dose
of IS agents before taper; 73% started 1 to 2 mg/kg of
glucocorticoid therapy; and 16% started both 1 to
Figure 2. Frequency distribution of estimated rates of recurrent
aGVHD following IS taper. PBSCT 5 ablative conditioning, peripheral
blood stem cells; BMT 5 ablative conditioning, bone marrow; MUD 5
ablative conditioning, unrelated donor peripheral blood stem cells;
RIC5 reduced-intensity conditioning, peripheral blood stem cells; post-
resolved GVHD 5 recurrent aGVHD in setting of IS taper following
prior successfully treated episode of aGVHD (P\.05 for comparisons
between each group, with exception of the comparison of myeloablative
PBSCTand RIC PBSCT).
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IS agent not part of the original pretaper regimen.
Respondents indicated the proportion of these cases
of recurrent aGVHD in the setting of IS taper, which
can be successfully treated to complete resolution:
\20% of cases (1%); 20% to 39% of cases (15%);
40% to 59% of cases (52%); 60% to 79% of cases
(31%), and 80% to 100% of cases (2%). The self-
reported burden of cases of recurrent aGVHD realized
in the setting of IS taper that cannot be treated to
resolution thus highlights the gravity of this problem.
Following the final vignette depicting a case of
cGVHD successfully treated with systemic glucocorti-
coids, respondents indicated the proportion of cases inFigure 3. Estimated recurrent cGVHD in the setting of IS taper
following successful control of a prior episode of cGVHD.which recurrent cGVHD develops upon IS taper
(Figure 3). These data support an overall large burden
of recurrent cGVHD in the setting of IS taper.
A greater proportion of reported recurrent cGVHD
was associated with greater use of PBSCs over BM
(P 5 .036).Discontinuation of IS
Following each clinical vignette, survey respon-
dents estimated the proportion of their own HCT
patients, consistent with each of the described clinical
scenarios, who are able to completely discontinue IS
by 2 and 5 years. The frequency distribution for IS dis-
continuation across these clinical vignettes is depicted
in Figures 4 and 5. Reported IS discontinuation rates at
2 and 5 years significantly differed according to clinical
vignette in all comparisons, with the exception of
myeloablative conditioning with PBSCT versus RIC
PBSCT.Decision-Making Confidence
The majority (51%) indicated that they had no
institutional practice guideline or protocol for IS
taper. Forty-one percent indicated that their current
strategy for IS taper after HCT is not adequate; per-
ceived inadequacy was associated with the absence of
guidelines (P 5 .0007). Twenty-six percent indicated
that they were either uncomfortable or very uncomfort-
able with IS taper and management decisions. Increas-
ing level of comfort in decision making was associated
with adult HCT physician status (P 5 .049), academic
practice setting (P 5 .03), greater proportion of cord
blood HCT among unrelated donor sources (P 5
.016), and smaller proportion of PBSCT compared
with BMT (P 5 .02). A total of 62% either disagreedFigure 4. Frequency distribution of estimated rate of IS discontinuation
at 2 years after HCT according to clinical vignette. MRD 5 matched
related donor; MUD5matched unrelated donor; MAC5myeloablative
conditioning; RIC 5 reduced-intensity conditioning; PBSC 5 peripheral
blood stem cells; BM 5 bone marrow stem cells. The proportions off
IS are compared between each of these clinical vignettes by Bowker’s
test with P\ .05 for each, except the comparison of MRD/MAC/PBSC
and MRD/RIC/PBSC vignettes, where P 5 NS.
Figure 5. Frequency distribution of estimated rate of IS discontinuation
at 5 years after HCT according to clinical vignette. MRD 5 matched
related donor; MUD5matched unrelated donor; MAC5myeloablative
conditioning; RIC 5 reduced-intensity conditioning; PBSC 5 peripheral
blood stem cells; BM 5 bone marrow stem cells. The proportions off
IS are compared between each of these clinical vignettes by Bowker’s
test with P\ .05 for each, except the comparison of MRD/MAC/PBSC
and MRD/RIC/PBSC vignettes, where P 5 NS.
1534 Biol Blood Marrow Transplant 17:1528-1536, 2011J. Pidala et al.or strongly disagreed with the statement, ‘‘I am able to
distinguish those patients who will have recurrent
GVHD after IS taper versus those who will not’’;
26% neither disagreed nor agreed; and 12% agreed.
Increasing level of agreement with this statement was
associated with the absence of institutional guidelines
or protocol (P 5 .01), and shorter duration of practice
as an HCT physician (P 5 .005).Qualitative Results
Survey respondents were afforded an opportunity to
offer comments on their perceptions of the survey itself.
These instructive comments highlighted both limita-
tions of this instrument, as well as colorfully depicted
the variation in HCT physician practice. First, some
(18 respondents total) reported that the vignettes did
not capture all subtle nuances relevant to decision
making. In summary, these included the following: in-
adequate details on combination of patient age, comor-
bidity, disease risk, and performance status; inadequate
information for estimation of anticipated tolerance of
GVHD; no mention of the use of antithymocyte glob-
ulin (ATG) or alemtuzumab in GVHD prophylaxis;
and no allowance for staged response of multiple thera-
peutic options in sequence. Other comments presented
extremes of practice variation, ranging from all
decisions uniformly being driven by protocol to, alter-
natively, a total absence of guidelines or a standardized
approach. One respondent stated, ‘‘We need standard
guidelines for IS taper and treatment of aGVHD and
cGVHD. Failure is due in part to intra- and interinsti-
tutional variation in the absence of these guidelines.’’DISCUSSION
Variation in management of IS following HCT
is anticipated, given the lack of evidence- or
consensus-based practice guidelines. However, this
practice variation has not been systematically studied
to date. We have conducted a national survey of trans-
plant physician management of IS following HCT,
with the principal aims of examining variation in prac-
tice of IS management, describing the perceived
burden of recurrent GVHD incurred in this setting,
as well as the estimated rates of successful discontinu-
ation of IS post-HCT. The resulting data demonstrate
marked variation in the management of IS, with
heterogeneity in timing of taper onset, IS agents
utilized and sequence of tapering, the frequency of
taper, and the strategy employed in patients with and
without GVHD. Strikingly, 25% of respondents re-
ported that they have no strategy that they consistently
follow.
The data demonstrate that practice varies accord-
ing to a number of transplant variables: In the setting
of unrelated donor HCT, the majority of transplant
physicians indicated caution, starting IS taper later
than matched sibling HCT; a smaller proportion
also endorsed tapering less frequently and by lesser
amounts. The majority endorsed differential manage-
ment of IS following RIC, both tapering earlier after
HCT, and with particular attention to donor chime-
rism. In the setting of relapse, a robust majority
stopped all IS, and a lesser proportion favored the
use of DLI. Not surprisingly, of those who utilized
DLI for the treatment of relapse, the majority indi-
cated that they were willing to accept the risk of
aGVHD inherent with this procedure.
Several other relationships emerged in the examina-
tion of response according to physician and transplant
center characteristics: Pediatric HCT physicians
tapered IS earlier and more frequently. Adult HCT
physicians were more likely to indicate no difference
in management according to stem cell source and con-
ditioning regimen intensity and to report more comfort
in their decision making surrounding IS management
compared with pediatricians. Duration of practice as
an HCT physician also emerged as an important deter-
minant of practice: Those with shorter duration of ex-
perience were more likely to endorse no escalation in
therapy when confronted with aGVHD after DLI.
Conversely, those with longer duration of practice
were more likely to accept the risk of GVHD inherent
in the use of DLI for post-HCT relapse. These data
may reflect differences in maturity in decision making,
as well as differential focus on the poor outcome associ-
ated with relapsed disease post-HCT. Interestingly,
those with shorter practice duration were more likely
to endorse that they could distinguish those who will
develop GVHD versus not in the setting of IS taper.
Biol Blood Marrow Transplant 17:1528-1536, 2011 1535Variation in Immune Suppression ManagementThis likely represents limited experience because it is
not clear that recent insights have emerged in the
clinical prediction of GVHD in the setting of IS taper
that could explain this disparity. Although there was
limited representation of self-identified community
HCT physicians in this sample, the data indicate that
community practice setting was associated with both
allowing more time after resolution of GVHD before
IS taper, as well as a lesser degree of confidence in
decision making. Finally, the utilization of PBSC
emerged as a consistent transplant center variable
important for physician decision making and their
reported outcomes: Greater utilization of PBSCs was
associated with less frequent taper of IS, less confidence
in decision making, greater projected burden of recur-
rent cGVHD on IS taper, greater perceived proportion
of recurrent aGVHD, and a smaller estimated propor-
tion of successful discontinuation of IS at 2 and 5 years
post-HCT.
Physicians consistently reported a large burden of
both recurrent aGVHD and cGVHD in the setting of
IS taper, but differed in their resultant therapeutic
approach: Many utilized glucocorticoid therapy in this
setting,whereas smaller proportions endorsed resuming
prior doses of IS agents or both starting glucocorticoids
and adding new IS agents. The consequences ofGVHD
emerging or recurring in the setting of IS taper is clearly
a grave problem, as supported by HCT physicians’
self-reported proportion of these cases that cannot be
treated to resolution.
The data also provide insight into transplant
physicians’ perceptions of rates of successful IS discon-
tinuation following HCT. These data indicate that
HCT physicians largely expect the majority of HCT
recipients to have discontinued IS by 5 years post-
HCT, and that their expectations differ according to
stem cell source and donor relation. Differences in
estimated IS discontinuation rates were not detected
according to conditioning regimen intensity.
Our measurement of decision-making confidence
provides additional insight into the shortcomings of
current practice. The majority of respondents indicated
that they have no institutional guidelines or protocols
that they follow in their practice of IS discontinuation
post-HCT. As well, 41% reported that their current
strategy for IS management post-HCT is not adequate.
Alarmingly, 26% admitted that they are either uncom-
fortable or very uncomfortable withmaking decisions in
the management of IS post-HCT. Although this was
a confidential survey, this is likely a low estimate, given
the conflict involved in acknowledging and reporting
uncertainty and discomfort in the HCT physician’s
scope of practice. As anticipated, the majority indicated
that they are not able to distinguish those who will or
will not develop GVHD upon taper of IS. This level
of uncertainty and discomfort involved in the decision
making of HCT physicians has potentially seriouscomplications, given the attendant risk and conse-
quences of GVHD emerging in the setting of IS taper.
Although these results are intriguing, we acknowl-
edge the limitation of low response rate, which
threatens the validity of these data. The response rate
appears lower than anticipated in physician surveys;
however, the true denominator of respondents is not
certain. Undeliverable or returned messages were not
tracked by the ASBMT. As well, reasons for nonpartic-
ipation are largely unknown, given the limited number
of those who actively declined to participate. Methods
employed to encourage response included both serial
invitations, as well as the later targeted requests to
nonresponders. Given the observed declining trend
in proportion responding per invitation, it is unlikely
that further invitations would have dramatically in-
creased the total response rate within a reasonable
time frame. Provision of both paper and electronic sur-
vey, as well as monetary incentive, may have increased
the response rate, but was not possible.
In summary, these data support a lack of consistent
practice and argue for more rigorous study of IS
management post-HCT. Moving forward from these
findings, we suggest several potential approaches to
determine best practice in IS taper and discontinuation
following HCT. Retrospective studies examining suc-
cessful IS discontinuation rates according to tapering
schedule may provide an initial understanding. Pro-
spective observational studies could capture physician
practice in IS taper and the associated outcomes. Les-
sons learned from these studies would be important to
develop a prospective randomized trial comparing best
approaches for tapering and discontinuation of IS.
Finally, if validated biomarkers of post-HCT immune
tolerance can be developed, these could facilitate
a personalized and informed strategy for IS discontin-
uation after HCT.ACKNOWLEDGMENTS
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